Cargando…
Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis
BACKGROUND: The clinical impact of early aspirin discontinuation compared with dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention with stenting remains poorly studied. We investigated the clinical outcomes of patients assigned to either early aspirin discontin...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955304/ https://www.ncbi.nlm.nih.gov/pubmed/33410332 http://dx.doi.org/10.1161/JAHA.120.018304 |
_version_ | 1783664221305700352 |
---|---|
author | Wiebe, Jens Ndrepepa, Gjin Kufner, Sebastian Lahmann, Anna L. Xhepa, Erion Kuna, Constantin Voll, Felix Gosetti, Rosanna Laugwitz, Karl‐Ludwig Joner, Michael Kastrati, Adnan Cassese, Salvatore |
author_facet | Wiebe, Jens Ndrepepa, Gjin Kufner, Sebastian Lahmann, Anna L. Xhepa, Erion Kuna, Constantin Voll, Felix Gosetti, Rosanna Laugwitz, Karl‐Ludwig Joner, Michael Kastrati, Adnan Cassese, Salvatore |
author_sort | Wiebe, Jens |
collection | PubMed |
description | BACKGROUND: The clinical impact of early aspirin discontinuation compared with dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention with stenting remains poorly studied. We investigated the clinical outcomes of patients assigned to either early aspirin discontinuation or DAPT after percutaneous coronary intervention with stenting. METHODS AND RESULTS: We performed a meta‐analysis of aggregate data from randomized clinical trials enrolling participants receiving a percutaneous coronary intervention with stenting and assigned to either early aspirin discontinuation or DAPT. Scientific databases were searched from inception through March 30, 2020. Trial‐level hazard ratios (HRs) and 95% CIs were pooled using a random effects model with inverse variance weighting. The primary outcome was all‐cause death. Secondary outcomes were myocardial infarction, stent thrombosis, stroke, and major bleeding. Overall, 36 206 participants were allocated to either early aspirin discontinuation (experimental therapy, n=18 088) or DAPT (control therapy, n=18 118) in 7 trials. Median follow‐up was 12 months. All‐cause death occurred in 2.5% of patients assigned to experimental and 2.9% of patients assigned control therapy (hazard ratio [HR], 0.91, 95% CI, 0.75–1.11; P=0.37). Overall, patients treated with experimental versus control therapy showed no significant difference in terms of myocardial infarction (HR, 1.02 [0.85–1.22], P=0.81), stent thrombosis (HR, 1.02 [0.87–1.20], P=0.83), or stroke (HR, 1.01 [0.68–1.49], P=0.96). However, the risk for major bleeding (HR, 0.58 [0.43–0.77], P<0.01) was significantly reduced by experimental as compared with control therapy. CONCLUSIONS: In patients treated with percutaneous coronary intervention and stenting, assigned to a strategy of early aspirin discontinuation versus DAPT, the risk of death and ischemic events is not significantly different but the risk of bleeding is lower. |
format | Online Article Text |
id | pubmed-7955304 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-79553042021-03-17 Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis Wiebe, Jens Ndrepepa, Gjin Kufner, Sebastian Lahmann, Anna L. Xhepa, Erion Kuna, Constantin Voll, Felix Gosetti, Rosanna Laugwitz, Karl‐Ludwig Joner, Michael Kastrati, Adnan Cassese, Salvatore J Am Heart Assoc Systematic Review and Meta‐analysis BACKGROUND: The clinical impact of early aspirin discontinuation compared with dual antiplatelet therapy (DAPT) in patients undergoing percutaneous coronary intervention with stenting remains poorly studied. We investigated the clinical outcomes of patients assigned to either early aspirin discontinuation or DAPT after percutaneous coronary intervention with stenting. METHODS AND RESULTS: We performed a meta‐analysis of aggregate data from randomized clinical trials enrolling participants receiving a percutaneous coronary intervention with stenting and assigned to either early aspirin discontinuation or DAPT. Scientific databases were searched from inception through March 30, 2020. Trial‐level hazard ratios (HRs) and 95% CIs were pooled using a random effects model with inverse variance weighting. The primary outcome was all‐cause death. Secondary outcomes were myocardial infarction, stent thrombosis, stroke, and major bleeding. Overall, 36 206 participants were allocated to either early aspirin discontinuation (experimental therapy, n=18 088) or DAPT (control therapy, n=18 118) in 7 trials. Median follow‐up was 12 months. All‐cause death occurred in 2.5% of patients assigned to experimental and 2.9% of patients assigned control therapy (hazard ratio [HR], 0.91, 95% CI, 0.75–1.11; P=0.37). Overall, patients treated with experimental versus control therapy showed no significant difference in terms of myocardial infarction (HR, 1.02 [0.85–1.22], P=0.81), stent thrombosis (HR, 1.02 [0.87–1.20], P=0.83), or stroke (HR, 1.01 [0.68–1.49], P=0.96). However, the risk for major bleeding (HR, 0.58 [0.43–0.77], P<0.01) was significantly reduced by experimental as compared with control therapy. CONCLUSIONS: In patients treated with percutaneous coronary intervention and stenting, assigned to a strategy of early aspirin discontinuation versus DAPT, the risk of death and ischemic events is not significantly different but the risk of bleeding is lower. John Wiley and Sons Inc. 2021-01-07 /pmc/articles/PMC7955304/ /pubmed/33410332 http://dx.doi.org/10.1161/JAHA.120.018304 Text en © 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Systematic Review and Meta‐analysis Wiebe, Jens Ndrepepa, Gjin Kufner, Sebastian Lahmann, Anna L. Xhepa, Erion Kuna, Constantin Voll, Felix Gosetti, Rosanna Laugwitz, Karl‐Ludwig Joner, Michael Kastrati, Adnan Cassese, Salvatore Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis |
title | Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis |
title_full | Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis |
title_fullStr | Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis |
title_full_unstemmed | Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis |
title_short | Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta‐Analysis |
title_sort | early aspirin discontinuation after coronary stenting: a systematic review and meta‐analysis |
topic | Systematic Review and Meta‐analysis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955304/ https://www.ncbi.nlm.nih.gov/pubmed/33410332 http://dx.doi.org/10.1161/JAHA.120.018304 |
work_keys_str_mv | AT wiebejens earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis AT ndrepepagjin earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis AT kufnersebastian earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis AT lahmannannal earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis AT xhepaerion earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis AT kunaconstantin earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis AT vollfelix earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis AT gosettirosanna earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis AT laugwitzkarlludwig earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis AT jonermichael earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis AT kastratiadnan earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis AT cassesesalvatore earlyaspirindiscontinuationaftercoronarystentingasystematicreviewandmetaanalysis |